Tim Watkins's most recent trade in Contineum Therapeutics Inc. - Ordinary Shares - Class A was a trade of 3,611 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 3,611 | 249,167 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Sale of securities on an exchange or to another person at price $ 15.02 per share. | 02 Mar 2026 | 3,611 | 0 | - | 15.0 | 54,220 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.50 per share. | 02 Mar 2026 | 3,611 | 3,611 | - | 4.5 | 16,250 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2026 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 3,611 | 252,778 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.50 per share. | 28 Jan 2026 | 3,611 | 3,611 | - | 4.5 | 16,250 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Sale of securities on an exchange or to another person at price $ 14.09 per share. | 28 Jan 2026 | 2,800 | 811 | - | 14.1 | 39,441 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Sale of securities on an exchange or to another person at price $ 14.48 per share. | 28 Jan 2026 | 811 | 0 | - | 14.5 | 11,747 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2025 | 3,611 | 256,389 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 29 Dec 2025 | 3,611 | 0 | - | 12.1 | 43,558 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.50 per share. | 29 Dec 2025 | 3,611 | 3,611 | - | 4.5 | 16,250 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2025 | 260,000 | 260,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Tim Watkins | CMO & Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2025 | 26,000 | 26,000 | - | - | Stock Option (right to buy) |